The effects of diuretics and adrenergic-blocking agents on plasma lipids. 1986

J J Rohlfing, and J D Brunzell

ANTIHYPERTENSIVE MEDICATIONS CAUSE THE FOLLOWING CHANGES IN PLASMA LIPIDS AND LIPOPROTEINS: Thiazide and loop diuretics increase triglyceride, total cholesterol and low-density-lipoprotein (LDL) cholesterol levels with no change in high-density-lipoprotein (HDL) cholesterol. beta-Adrenergic antagonists increase triglyceride and decrease HDL cholesterol levels. A rise in very-low-density-lipoprotein (VLDL) cholesterol balances the decrease in HDL cholesterol, so that there is no significant change in total cholesterol. alpha-Adrenergic antagonists decrease triglyceride, increase HDL cholesterol and may decrease VLDL and LDL cholesterol. Labetalol, with both alpha- and beta-adrenergic antagonistic activity, does not affect plasma lipids in a small number of studies. The calcium channel blockers nifedipine and verapamil also have no consistent effect on lipoprotein levels in a small number of studies.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic

Related Publications

J J Rohlfing, and J D Brunzell
January 1971, Atherosclerosis,
J J Rohlfing, and J D Brunzell
February 1961, The American journal of physiology,
J J Rohlfing, and J D Brunzell
July 1970, Harefuah,
J J Rohlfing, and J D Brunzell
January 1974, The Journal of pharmacology and experimental therapeutics,
J J Rohlfing, and J D Brunzell
January 1992, Cleveland Clinic journal of medicine,
J J Rohlfing, and J D Brunzell
January 1987, Advances in experimental medicine and biology,
J J Rohlfing, and J D Brunzell
August 1968, European journal of pharmacology,
J J Rohlfing, and J D Brunzell
August 1972, The Journal of clinical investigation,
J J Rohlfing, and J D Brunzell
October 1966, Kumamoto Igakkai zasshi. The Journal of the Kumamoto Medical Society,
Copied contents to your clipboard!